Clearside Biomedical Inc (CLSD)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
George M. Lasezkay
Employees:
30
900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA, GEORGIA 30005
678-270-3631

Clearside Biomedical, Inc. focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprchoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX and CLS-301, an integrin inhibitor suspension for macular degeneration.

Data derived from most recent annual or quarterly report
Market Cap 68.728 Million Shares Outstanding61.364 Million Avg 30-day Volume 115.226 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.57
Price to Revenue64.6507 Debt to Equity0.0 EBITDA-30.122 Million
Price to Book Value23.5616 Operating Margin-3072.7642 Enterprise Value22.197 Million
Current Ratio8.541 EPS Growth-58 Quick Ratio8.31
1 Yr BETA 0.974 52-week High/Low 1.86 / 0.9 Profit Margin-3514.5325
Operating Cash Flow Growth-1776.5925 Altman Z-Score-9.618 Free Cash Flow to Firm 14.725 Million
Earnings Report2023-08-09
View SEC Filings from CLSD instead.

View recent insider trading info

Clearside Biomedical Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CLSD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CLSD

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-20 by CIULLA THOMAS
  • 4: filed on 2023-01-20 by LASEZKAY GEORGE M
  • 4: filed on 2023-01-20 by DEIGNAN CHARLES A.
  • 4: filed on 2023-01-11 by CIULLA THOMAS
  • 4: filed on 2023-01-06 by LASEZKAY GEORGE M
  • 4: filed on 2023-01-06 by DEIGNAN CHARLES A.
  • 4: filed on 2023-01-06 by CIULLA THOMAS
  • 4: filed on 2022-12-21 by THORP CLAY
  • 4: filed on 2022-12-20 by DEIGNAN CHARLES A.
  • 4: filed on 2022-12-19 by THORP CLAY

    • Events (8k)

  • 8-K: filed on 2023-05-12:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-18:
    Item 8.01: Other Events
  • 8-K: filed on 2023-03-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-02-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-08:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    CIULLA THOMAS CHIEF MEDICAL OFFICER

    • Officer
    		 291,890 2023-01-20 3

    LASEZKAY GEORGE M CEO

    • Officer
    • Director
    		 484,577 2023-01-19 2

    DEIGNAN CHARLES A. CHIEF FINANCIAL OFFICER

    • Officer
    		 363,472 2023-01-19 3

    THORP CLAY

    • Director
    		 3,575,562 2022-12-21 3

    HUTSON NANCY J

    • Director
    		 83,000 2022-11-17 2

    YERXA BENJAMIN R

    • Director
    		 30,000 2022-06-22 1

    SHAFFER CHRISTY L

    • Director
    		 30,000 2022-06-22 1

    EDWARDS JEFFREY L

    • Director
    		 30,000 2022-06-22 1

    CROARKIN RICHARD

    • Director
    		 30,000 2022-06-22 1

    HUMPHRIES WILLIAM D.

    • Director
    		 30,000 2022-06-22 1

    WHITMORE BRADFORD T

    • 10% Owner
    		 8,680,842 2021-08-30 0

    RAYMOND BRION S. CHIEF COMMERCIAL OFFICER

    • Officer
    		 50,000 2019-05-31 0

    WHITE DANIEL H. PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2019-02-05 0

    CAGLE GERALD D.

    • Director
    		 94,209 2018-06-25 0

    ZAYTSEV EVGENY

    • Director
    		 0 2018-06-20 0

    NORONHA GLENN CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2017-12-08 0

    YOON DEREK

    • Director
    		 0 2017-06-30 0

    HATTERAS VENTURE ADVISORS III, LLC

    HATTERAS VENTURES PARTNERS III LP

    HATTERAS VENTURE AFFILIATES III LP

    CRUMPLER JOHN

    INGRAM ROBERT ALEXANDER

    LEE KENNETH B JR

    REED DOUGLAS MD

    THORP CLAY

    • 10% Owner
    • MAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUP
    		 No longer subject to file 2017-01-17 0

    HATTERAS VENTURE ADVISORS IV SBIC, LLC

    HATTERAS VENTURE PARTNERS IV SBIC, LP

    CRUMPLER JOHN

    INGRAM ROBERT ALEXANDER

    LEE KENNETH B JR

    REED DOUGLAS MD

    THORP CLAY

    • 10% Owner
    • MAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUPMAY BE PART OF A 13(D) GROUP
    		 No longer subject to file 2017-01-17 0

    RMI INVESTMENTS S.A.R.L.

    RUSNANOMEDINVEST LLC

    • 10% Owner
    		 No longer subject to file 2016-06-07 0

    CORMORANT ASSET MANAGEMENT, LLC

    CORMORANT GLOBAL HEALTHCARE GP, LLC

    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

    CHEN BIHUA

    • Director
    • 10% Owner
    		 1,988,208 2016-06-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 22:15:04 UTC 4.0101 1.0499 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 21:45:04 UTC 4.0101 1.0499 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 21:15:04 UTC 4.0101 1.0499 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 20:45:03 UTC 4.0101 1.0499 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 20:15:05 UTC 4.0101 1.0499 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 19:45:04 UTC 4.0101 1.0499 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 19:15:04 UTC 4.0101 1.0499 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 18:45:04 UTC 4.0101 1.0499 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 18:15:04 UTC 4.0101 1.0499 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 17:45:03 UTC 4.0101 1.0499 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 17:15:04 UTC 4.0101 1.0499 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 16:45:03 UTC 3.9753 1.0947 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 16:15:04 UTC 3.9753 1.0947 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 15:45:04 UTC 3.9753 1.0947 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 15:15:03 UTC 3.9753 1.0947 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 14:45:04 UTC 3.9753 1.0947 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 14:15:03 UTC 3.9753 1.0947 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 13:45:03 UTC 4.0045 1.0655 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 13:15:04 UTC 4.0045 1.0655 1000000
    CLEARSIDE BIOMEDICAL INC CLSD 2023-06-02 12:45:03 UTC 4.0045 1.0655 1000000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments